Peterson Capital in collaboration with Westmount Capital will introduce next wednesday in Milan, Alpha Cognition, a Canadian clinical-stage biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer’s Disease and Amyotrophic Lateral Sclerosis. ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side effects and novel routes of administration.
Why invest in Alpha Cognition?
Experienced Leadership Team – History Of Multi-billion Drug Launches
- Over 20 product launches including, and over 25 approvals in the USA and Europe.
• Multiple billion dollar drug launches (ZyprexaTM, XtandiTM, CelebrexTM, SeroquelTM) by leadership team
ALPHA 1062 – Best-in-class Treatment Potential
- De-risked 505(b)(2) new drug application with a high probability of success • 505(b)(2) application to be supplemented with RESOLVE study
• Patent protected: patents extending to 2042
Approval Targeted Q1/24; Commercialization Q4/24; Revenue generating 2024
Large $5.5B, 11M prescription market characterized by high drug discontinuation
Share Structure (as of November 3rd, 2022: C$0.40)
Shares outstanding: 61,023,450; Market Cap: C$24,4 million.
https://money.tmx.com/en/quote/ACOG
For more information about how Alpha Cognition is developing a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, visit https://www.alphacognition.com/
Here is a recent Fact Sheet:
https://www.petersoncapital.ca/alpha-cognition-portfolio
Company will be presented by: Michael McFadden, CEO
Michael McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology, and urology.
He has over 16 years’ experience in Neuroscience. Previous leadership roles have included Chief Commercial Officer at MPower Health, Chief Commercial Officer at Urovant Sciences (Nasdaq: UROV), and SVP Sales and Marketing at Avanir Pharmaceuticals (Nasdaq: AVNR). Prior to these roles, Mr. McFadden held leadership roles at Amylin Pharmaceuticals (Nasdaq: AMLN) and Pharmacia. He serves on advisory boards at MPower Health and MindLab.
care of the redaction
